Tirzepatide (Mounjaro) induces acute small bowel obstruction in a 50-year-old woman
Background
While tirzepatide (Mounjaro) is highly effective for type 2 diabetes mellitus and obesity, its mechanism of action, involving dual agonism of GIP and GLP-1 receptors, inherently impacts gastrointestinal motility. Common side effects include nausea, vomiting, and delayed gastric emptying. However, acute small bowel obstruction (SBO) is a rare and poorly understood complication, posing a significant clinical challenge due to its potential severity and the need for prompt recognition and management. This case highlights a critical gap in understanding the full spectrum of severe GI adverse events associated with incretin-based therapies.
Study Design
This case report details a 50-year-old woman with insulin-dependent type 2 diabetes mellitus, diabetic neuropathy, and obesity who developed acute small bowel obstruction. She had been receiving tirzepatide therapy, titrated to 12.5 mg weekly, for three months prior to presentation. The patient presented with severe abdominal pain, vomiting, abdominal distension, and syncope. Diagnostic imaging confirmed small bowel obstruction, specifically ruling out perforation, ischemia, or any identifiable mechanical lesion. Conservative management included nasogastric decompression, bowel rest, and intravenous fluid resuscitation. Tirzepatide was discontinued, and the patient was followed for two months.
Results
The patient presented with severe abdominal pain, vomiting, abdominal distension, and syncope, indicative of acute gastrointestinal distress. Imaging studies conclusively confirmed acute small bowel obstruction, notably without any evidence of perforation, ischemia, a mass lesion, or a clear mechanical transition point. This absence of an alternative reversible etiology strongly implicated the medication. Conservative management, comprising nasogastric decompression, bowel rest, and intravenous fluid resuscitation, led to rapid clinical improvement. Upon discontinuation of tirzepatide, no recurrence of small bowel obstruction was observed over a two-month follow-up period. This suggests a direct, reversible link between tirzepatide use and the onset of SBO. The likely mechanism is impaired gastrointestinal motility, a known effect of incretin-based therapies. > Discontinuation of tirzepatide and conservative management led to rapid resolution of acute small bowel obstruction, with no recurrence over 2 months.
Key Findings
- A 50-year-old woman developed acute small bowel obstruction after 3 months of tirzepatide therapy.
- Patient was receiving tirzepatide 12.5 mg weekly.
- Imaging confirmed small bowel obstruction without mechanical cause, perforation, or ischemia.
- Conservative management and tirzepatide discontinuation led to rapid clinical improvement.
- No recurrence of SBO was observed over 2 months of follow-up after drug cessation.
Why It Matters
This case report underscores that acute small bowel obstruction is a rare but serious adverse effect of tirzepatide, demanding heightened clinical vigilance. For clinicians and patients, this means considering SBO in the differential diagnosis for severe abdominal symptoms in individuals on GLP-1/GIP agonists, especially those with pre-existing dysmotility risk factors. While not a change to standard dosing protocols, it emphasizes the importance of patient education on severe GI symptoms and prompt medical evaluation. The clinical translation outlook suggests a need for further research into patient risk stratification and the specific mechanisms by which these drugs can induce severe motility disorders, potentially influencing future prescribing guidelines for vulnerable populations.